Message Font: Serif | Sans-Serif
No. of Recommendations: 0
I bought in 2 months ago around $6 when they announced the news concerning the success of the Tolamba trials in fighting ragweed allergies. Stock had another nice pop earlier this week on the announcement concerning the success of the Heplisav trials in combatting Hepititas B.

My question is twofold; is anyone aware of when the Tolamba trials are due to be completed and does anyone have any idea of the potential annual market (in $) for both Tolamba and Heplisav? I'm curious because at $9 and change, the market cap for this company is only $277M. I would think that the potential market for either of these 2 drugs would make this company a steal @ $9?
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.